Sun Pharma, PPP, ICMR - Current Affairs Questions and Answers

1)   ICMR signed an MoU with which institute for collaboration on vaccine research and development?

a. International Vaccine Institute
b. Serum Institute of India
c. National Genomics Institute of India
d. Only a and c
e. All the above
Answer  Explanation 

ANSWER: International Vaccine Institute

Explanation:
The Indian Council of Medical Research (ICMR) has signed an MoU with the International Vaccine Institute (IVI).

This is for collaborating on vaccine research and development.

India will commit $5,00,000 (₹3.20 crore) annually for a stake in IVI - an amount approved during a Cabinet meeting in January

The MoU was signed between Soumya Swaminathan, the Director General of ICMR and Secretary, Department of Health Research, Manoj Jhalani, Additional Secretary and managing director, National Health Mission, and IVI Director General Jerome H. Kim.

IVI has been partnering with Indian vaccine manufacturers, research institutes, government, and public health agencies on vaccine development, research, and training.

One of the most successful collaborations was with Shantha Biotech on the development of Shanchol, the world’s first low-cost oral cholera vaccine.

The vaccine was licensed in India in 2009 and WHO-prequalified in 2011.

India is a vaccine industry powerhouse that supplies 60% of the world’s vaccines.

The signing of the MoU is a continuation of our partnership with India to provide safe, effective and affordable vaccines for people around the world.
2)   Which of the following is/are recommendations of Kelkar report on PPP?

1. Setting up of an Infrastructure PPP Project Review Committee (IPRC).
2. Setting up of Infrastructure PPP Adjudication Tribunal (IPAT) chaired by a judicial member (former SC Judge or HC Chief Justice) with a technical and financial member.

a. Only 1
b. Only 2
c. Both
d. None
Answer  Explanation 

ANSWER: Both

Explanation:
The panel, headed by former finance secretary Vijay Kelkar, recommended setting up independent regulators for PPP projects in various sectors and pushed for amendment to the Prevention of Corruption Act to clarify the difference between cases of graft and genuine errors in decision-making.
3)   Which drug pharma major has entered into an agreement to acquire US based eyesore firm Insite Vision for USD 48 million plus related debt and transaction costs:

a. Ranbaxy
b. Sun Pharma
c. Abbott
d. None of the above
Answer  Explanation 

ANSWER: Sun Pharma

Explanation:
This move will strengthen Sun’s branded ophthalmic portfolio in the US. The deal gives Sun Pharma access to four late stage branded ophthalmic products in the US. For the 6-month period ending June, InSite Vision recorded revenues of $3.8 million, an EBITDA loss of USD 6.4 million and a net loss of $7.5 million.

Related Content

▲